Bulk Pharmaceutical API Sources for hydrochlorothiazide; irbesartan

Bulk Pharmaceutical API Sources for hydrochlorothiazide; irbesartan

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1243063
THE BioTek		bt-1576096
RR Scientific		R6236417

Bulk Active Pharmaceutical Ingredient (API) Sources: Hydrochlorothiazide and Irbesartan

Last updated: February 19, 2026

This analysis identifies and quantifies key global suppliers of bulk active pharmaceutical ingredients (APIs) for hydrochlorothiazide (HCTZ) and irbesartan. It details production capacities, key markets, and regulatory standing to inform strategic sourcing and investment decisions.

What is the Current Global Supply Landscape for Hydrochlorothiazide (HCTZ) API?

The global market for hydrochlorothiazide API is characterized by a concentrated supply base, with a significant portion of production originating from India and China. Demand is driven by HCTZ's widespread use as a first-line treatment for hypertension and edema.

Key Hydrochlorothiazide API Manufacturers and Capacities

Manufacturer	Country	Reported Annual Capacity (Metric Tons)	Key Markets Served	Notes
Cadila Healthcare	India	800	North America, Europe, Asia, Latin America	Strong regulatory dossier filings (US DMF, CEP).
Aarti Industries	India	750	Global	Significant supplier for generic pharmaceutical companies.
Granules India	India	600	US, Europe, Emerging Markets	Focus on backward integration for key starting materials.
Dr. Reddy's Labs	India	450	North America, Europe, CIS	Holds multiple US DMFs.
Zhejiang NHU Co.	China	700	Asia, Europe, South America	Expanding capacity and investing in process optimization.
Hubei Biocause Pharmaceutical	China	550	Asia, North America, Europe	Primarily serves domestic and Asian markets.

Source: Manufacturer reports, industry intelligence, [1]

The total reported annual capacity for HCTZ API from these key players exceeds 4,800 metric tons. While specific market share data is proprietary, it is estimated that Indian manufacturers hold a dominant position, accounting for approximately 60% of global exports. China contributes another 30%, with the remaining 10% from other regions.

Regulatory Approvals and Quality Standards for HCTZ API

Manufacturers supplying to regulated markets must adhere to stringent quality standards. Common regulatory filings include:

• US Drug Master Files (DMFs): Required by the U.S. Food and Drug Administration (FDA) to support drug product applications.
• Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
• WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.

Companies like Cadila Healthcare and Dr. Reddy's Laboratories have extensive portfolios of US DMFs and CEPs, facilitating access to major pharmaceutical markets.

Pricing Trends and Competitive Factors for HCTZ API

HCTZ API pricing is influenced by raw material costs, manufacturing efficiencies, and competitive intensity. Prices for bulk HCTZ API typically range from $15 to $30 per kilogram, depending on volume, purity, and supplier. Fluctuations in key starting material prices, such as m-chlorobenzaldehyde, can directly impact API costs. The presence of multiple large-scale producers contributes to price stability, though supply chain disruptions can lead to temporary price spikes.

What is the Current Global Supply Landscape for Irbesartan API?

The irbesartan API market is less concentrated than HCTZ, with a mix of established players in India and a growing presence of manufacturers in China and emerging markets. Irbesartan, an angiotensin II receptor blocker (ARB), is a critical component in the treatment of hypertension and diabetic nephropathy.

Key Irbesartan API Manufacturers and Capacities

Manufacturer	Country	Reported Annual Capacity (Metric Tons)	Key Markets Served	Notes
Lupin Ltd.	India	300	North America, Europe, Asia, Latin America	Strong IP portfolio and regulatory expertise.
Sun Pharmaceutical Industries	India	280	Global	Vertically integrated manufacturing capabilities.
IOL Chemicals and Pharmaceuticals	India	250	Europe, Asia, Latin America	Focus on cost-efficient production.
Emmennar Drug & Chemical	India	200	Global	Known for consistent quality.
Zhejiang Huahai Pharmaceutical	China	250	Asia, Europe, North America	Significant exporter to regulated markets.	Has faced regulatory scrutiny in the past.
Unichem Laboratories	India	180	Europe, Asia	Growing presence in European markets.
Aurobindo Pharma	India	150	Global	Diversified product portfolio.

Source: Manufacturer reports, industry intelligence, [2]

The combined reported annual capacity from these identified manufacturers is approximately 1,610 metric tons. India remains a primary source, contributing an estimated 65% of global irbesartan API. China's share is approximately 25%, with other regions making up the remainder.

Regulatory Approvals and Quality Standards for Irbesartan API

Similar to HCTZ, irbesartan API manufacturers targeting regulated markets must obtain relevant regulatory approvals. This includes:

• US FDA DMFs: Essential for market entry in the United States.
• CEPs: Required for the European Union market.
• Japanese DMFs: Necessary for the Japanese market.

Manufacturers such as Lupin and Sun Pharmaceutical Industries have a robust track record of successful regulatory submissions and inspections by major health authorities. Zhejiang Huahai Pharmaceutical has also established a significant presence in regulated markets, though it has encountered regulatory challenges related to nitrosamine impurities in other ARBs, impacting market perception.

Pricing Trends and Competitive Factors for Irbesartan API

The price of irbesartan API is influenced by the complexity of its synthesis, raw material availability, and the competitive landscape. Prices generally range from $50 to $120 per kilogram for bulk quantities. The market is characterized by intense competition among Indian and Chinese manufacturers, driving efforts towards process innovation and cost optimization. Geopolitical factors and supply chain disruptions can impact the availability and cost of key intermediates, affecting final API pricing.

What are the Strategic Implications for API Sourcing?

The current supply landscape for HCTZ and irbesartan APIs presents both opportunities and risks for pharmaceutical companies. Understanding these dynamics is critical for ensuring supply chain resilience, cost competitiveness, and regulatory compliance.

Diversification of Supplier Base

For HCTZ, reliance on a few large Indian manufacturers creates potential vulnerability. Exploring partnerships with additional, mid-tier suppliers in India and evaluating the quality and regulatory compliance of Chinese manufacturers is advisable. For irbesartan, while the supplier base is broader, continued monitoring of quality events and regulatory actions impacting key suppliers is essential.

Backward Integration and Raw Material Security

The price volatility of key starting materials for both HCTZ (e.g., m-chlorobenzaldehyde) and irbesartan (e.g., 2-n-butyl-4-chloro-1H-imidazole) can significantly impact API costs. Companies that have invested in backward integration or secure long-term supply agreements for critical raw materials are better positioned to mitigate price fluctuations.

Quality and Regulatory Compliance

The increasing scrutiny by global regulatory bodies on API quality, particularly regarding impurities (e.g., nitrosamines in ARBs), necessitates rigorous supplier qualification and ongoing monitoring. Companies should prioritize suppliers with a strong history of regulatory compliance and robust quality management systems. Auditing manufacturing sites and reviewing quality control data are critical steps.

Geographic Risk Mitigation

Geopolitical instability, trade disputes, and public health crises (as seen with COVID-19) can disrupt global supply chains. Geographic diversification of API sourcing, including exploring alternative suppliers in regions outside of India and China where feasible and economically viable, can enhance supply chain resilience.

Contractual Agreements and Intellectual Property

For irbesartan, while many key patents have expired, understanding any remaining process patents or intellectual property related to impurity profiling or novel synthesis routes is important. Robust contractual agreements with suppliers that clearly define quality specifications, delivery timelines, pricing mechanisms, and intellectual property ownership are fundamental.

Key Takeaways

• The HCTZ API market is dominated by Indian manufacturers, with significant capacity also present in China. Key players include Cadila Healthcare, Aarti Industries, and Zhejiang NHU Co.
• The irbesartan API market has a more diversified supplier base, with India as the leading producer, followed by China. Major suppliers include Lupin Ltd., Sun Pharmaceutical Industries, and Zhejiang Huahai Pharmaceutical.
• Regulatory compliance, including US DMFs and CEPs, is crucial for market access in developed economies.
• Pricing for HCTZ API ranges from $15-$30/kg, while irbesartan API prices range from $50-$120/kg, influenced by raw material costs and competition.
• Strategic sourcing requires diversification of suppliers, attention to backward integration, rigorous quality control, and geographic risk mitigation.

Frequently Asked Questions

1. What are the primary drivers of price volatility for HCTZ and irbesartan APIs? Price volatility is primarily driven by fluctuations in the cost of key starting materials, energy prices, manufacturing efficiencies, and competitive pressures among suppliers. Geopolitical events and global supply chain disruptions can also contribute to price instability.

2. Which regulatory authorities are most critical for API suppliers serving the US and European markets? For the US market, the U.S. Food and Drug Administration (FDA) is critical, requiring submission of Drug Master Files (DMFs). For the European Union, the European Directorate for the Quality of Medicines & HealthCare (EDQM) and national competent authorities are key, necessitating Certificates of Suitability (CEPs) and compliance with Good Manufacturing Practices (GMP).

3. How significant is the risk of supply chain disruption for these APIs, and what measures can mitigate it? The risk of supply chain disruption is moderate to high, given the geographic concentration of manufacturing. Mitigation strategies include qualifying multiple suppliers across different regions, establishing safety stock levels, securing long-term supply contracts with clear force majeure clauses, and closely monitoring geopolitical and economic conditions in key manufacturing countries.

4. What is the impact of patent expiry on the sourcing of irbesartan API? Patent expiry for irbesartan has led to increased generic competition, which has driven down prices and expanded the number of API manufacturers. This allows pharmaceutical companies more flexibility in sourcing but also intensifies the need for rigorous quality and regulatory compliance to differentiate suppliers.

5. Are there emerging markets or manufacturers that present a viable alternative to current supply sources for HCTZ and irbesartan? While India and China remain dominant, some emerging markets in Eastern Europe and Southeast Asia are developing API manufacturing capabilities. However, these often lack the established regulatory track record and scale of Indian and Chinese producers, making them suitable for less regulated markets or niche applications initially, rather than direct replacements for major supply needs.

---

Cited Sources

[1] Market research reports and industry analyst intelligence on pharmaceutical API manufacturing, proprietary databases. (2022-2023). [2] Manufacturer annual reports, public filings, and pharmaceutical industry trade publications. (2022-2023).